AU2010305420B2 - GLP-2 for use in intestine and muscle recovery - Google Patents

GLP-2 for use in intestine and muscle recovery Download PDF

Info

Publication number
AU2010305420B2
AU2010305420B2 AU2010305420A AU2010305420A AU2010305420B2 AU 2010305420 B2 AU2010305420 B2 AU 2010305420B2 AU 2010305420 A AU2010305420 A AU 2010305420A AU 2010305420 A AU2010305420 A AU 2010305420A AU 2010305420 B2 AU2010305420 B2 AU 2010305420B2
Authority
AU
Australia
Prior art keywords
glp
composition
rats
skeletal muscle
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010305420A
Other languages
English (en)
Other versions
AU2010305420A1 (en
Inventor
Didier Attaix
Denis Breuille
Audrey Codran-Raison
Lydie Combaret
Irene Corthesy-Theulaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2010305420A1 publication Critical patent/AU2010305420A1/en
Application granted granted Critical
Publication of AU2010305420B2 publication Critical patent/AU2010305420B2/en
Assigned to Société des Produits Nestlé S.A. , I.N.R.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: I.N.R.A., NESTEC S.A.
Assigned to Société des Produits Nestlé S.A. , Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement reassignment Société des Produits Nestlé S.A. Request to Amend Deed and Register Assignors: Société des Produits Nestlé S.A. , I.N.R.A.
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Société des Produits Nestlé S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010305420A 2009-10-07 2010-10-07 GLP-2 for use in intestine and muscle recovery Active AU2010305420B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172398.1 2009-10-07
EP09172398A EP2311486A1 (en) 2009-10-07 2009-10-07 GLP-2 for use in intestine and muscle recovery
PCT/EP2010/065021 WO2011042501A2 (en) 2009-10-07 2010-10-07 The intestine and muscle recovery

Publications (2)

Publication Number Publication Date
AU2010305420A1 AU2010305420A1 (en) 2012-05-10
AU2010305420B2 true AU2010305420B2 (en) 2015-03-19

Family

ID=41611235

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010305420A Active AU2010305420B2 (en) 2009-10-07 2010-10-07 GLP-2 for use in intestine and muscle recovery

Country Status (11)

Country Link
US (1) US20120270786A1 (enExample)
EP (2) EP2311486A1 (enExample)
JP (1) JP5801814B2 (enExample)
CN (1) CN102711803B (enExample)
AU (1) AU2010305420B2 (enExample)
BR (1) BR112012009380A2 (enExample)
CA (1) CA2776964C (enExample)
DK (1) DK2485756T3 (enExample)
ES (1) ES2539917T3 (enExample)
IN (1) IN2012DN03187A (enExample)
WO (1) WO2011042501A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051814A1 (en) * 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
JP6325215B2 (ja) * 2013-08-29 2018-05-16 テルモ株式会社 栄養補給用冷菓
ES2960218T3 (es) * 2014-10-14 2024-03-01 Nestle Sa Mejora en la funcionalidad del músculo de hombres ancianos
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR102119188B1 (ko) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952295A (en) * 1997-01-14 1999-09-14 Nestec S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20040052862A1 (en) * 2000-09-18 2004-03-18 Henriksen Dennis B. Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20060105954A1 (en) * 1995-04-14 2006-05-18 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO2008056155A1 (en) * 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661123A (en) * 1995-01-17 1997-08-26 Nestec, Ltd. Enteral composition for malabsorbing patients
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CN1268640C (zh) * 1996-04-12 2006-08-09 1149336安大略公司 胰高血糖素样肽－2的类似物
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
ATE396738T1 (de) * 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
WO2002066511A2 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
PL376223A1 (en) * 2002-10-14 2005-12-27 Novo Nordisk As Glucagon - like peptide - 2 variants
US20040115708A1 (en) * 2002-10-28 2004-06-17 Ardies C. Murray Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia
JP4699374B2 (ja) * 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ 安定なペプチド及びポリペプチドアナログ治療剤
JP5788631B2 (ja) * 2005-04-06 2015-10-07 ネステク ソシエテ アノニム グルコース制御およびインスリン作用を栄養的に改善するための方法および組成物
CN101365350A (zh) * 2006-01-09 2009-02-11 雀巢技术公司 应激患者的治疗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105954A1 (en) * 1995-04-14 2006-05-18 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5952295A (en) * 1997-01-14 1999-09-14 Nestec S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20040052862A1 (en) * 2000-09-18 2004-03-18 Henriksen Dennis B. Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2008056155A1 (en) * 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues

Also Published As

Publication number Publication date
AU2010305420A1 (en) 2012-05-10
HK1173949A1 (en) 2013-05-31
EP2485756A2 (en) 2012-08-15
BR112012009380A2 (pt) 2021-06-22
ES2539917T3 (es) 2015-07-07
WO2011042501A3 (en) 2011-06-03
JP2013507341A (ja) 2013-03-04
US20120270786A1 (en) 2012-10-25
CN102711803B (zh) 2017-02-22
IN2012DN03187A (enExample) 2015-09-25
CN102711803A (zh) 2012-10-03
EP2485756B1 (en) 2015-05-20
EP2311486A1 (en) 2011-04-20
CA2776964C (en) 2019-03-05
WO2011042501A2 (en) 2011-04-14
CA2776964A1 (en) 2011-04-14
DK2485756T3 (en) 2015-06-08
JP5801814B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
US8178487B2 (en) Method for providing glutamine
US8703725B2 (en) Nutritional compositions
US9549569B2 (en) Nutrition for obese patients
Moore et al. The biological value of protein
JP5315996B2 (ja) 総合経腸栄養組成物
AU2010305420B2 (en) GLP-2 for use in intestine and muscle recovery
JP2008506771A (ja) 血糖値を調節するためのアスパルテートを使用するための調製物
AU2017361804B2 (en) Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
US5849335A (en) Composition and method for providing glutamine
KR20070112811A (ko) 포도당내성을 개선시키기 위한 아미노산 조성물
WO2015009225A1 (en) Food composition product
HK1173949B (en) Glp-2 for use in the treatment of muscle atrophy
Hirsch et al. Functional changes in the gastrointestinal system
Mix FIT Food™ VEGAN
HK40012571A (en) Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: I.N.R.A.

Free format text: FORMER OWNER(S): I.N.R.A.; NESTEC S.A.

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): I.N.R.A.; NESTEC S.A.

HB Alteration of name in register

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER NAME(S): I.N.R.A.; SOCIETE DES PRODUITS NESTLE S.A.

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT

Free format text: FORMER NAME(S): I.N.R.A.; SOCIETE DES PRODUITS NESTLE S.A.

PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): SOCIETE DES PRODUITS NESTLE S.A.; INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT